Microbot Medical Stock News

HINGHAM, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a th

HINGHAM, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that it has and will continue to implement key initiatives that will prepare the LIBERTY® Robotic Sy

HINGHAM, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that it has and will continue to implement key initiatives that will prepare the LIBERTY® Robotic System for commercialization. In conjunction with recently announced design freeze, Dr. Eyal Morag, Microbots Chief Medical Officer, traveled to the United States to establish a clinical infrastructure with multiple sites and leading physicians for the commencement of a human clinical trial, which is expected to commence in the second half of 2022.

Live Demonstration of the LIBERTY Robotic System is Planned for January 10th in San Francisco, CA Live Demonstration of the LIBERTY Robotic System is Planned for January 10th in San Francisco, CA

Live Demonstration of the LIBERTY Robotic System is Planned for January 10th in San Francisco, CA Live Demonstration of the LIBERTY Robotic System is Planned for January 10th in San Francisco, CA

HINGHAM, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance for a second

HINGHAM, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance for a second patent application covering the Companys LIBERTY ® Robotic System. Globally, the Company now has 46 patents issued/allowed and 24 pending patent applications and is continuously submitting applications to protect its Intellectual Property.

Microbot Medical (NASDAQ:MBOT) announced its earnings results on Monday. The biotechnology company reported ($0.36) EPS for the quarter, hitting the consensus estimate of ($0.36), Fidelity Earnings reports. Microbot Medical stock traded down $0.05 during mid-day trading on Wednesday, hitting $6.73. The stock had a trading volume of 1 shares, compared to its average volume of []

HINGHAM, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance covering the C

HINGHAM, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Global patent jurisdictions continue to recognize Microbot Medical Inc.'s (Nasdaq: MBOT) innovative ‘One & Done' guidewire technology, as the Israel

Scientific Advisory Board Expanded with Additions of Global Medical Pioneers and Distinguished Thought Leaders Scientific Advisory Board Expanded with Additions of Global Medical Pioneers and Distingu

Results Validate Findings of Initial Study; End Points Achieved with No Intraoperative Adverse Events

HINGHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that Harel Gadot, CEO, President and Chief Executive Officer, will be presenting virtually at two upco